Literature DB >> 1737847

An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen.

J R Shapiro1, M L Stover, V E Burn, M B McKinstry, A L Burshell, S D Chipman, D W Rowe.   

Abstract

Mutations affecting the pro alpha 1(I) or pro alpha 2(I) collagen genes have been identified in each of the major clinical types of osteogenesis imperfecta. This study reports the presence of a heritable connective tissue disorder in a family with an osteopenic syndrome which has features of mild osteogenesis imperfecta but was considered idiopathic osteoporosis in the proband. At age 38, while still premenopausal, she was found to have osteopenia, short stature, hypermobile joints, mild hyperelastic skin, mild scoliosis, and blue sclerae. There was no history of vertebral or appendicular fracture. Hip and vertebral bone mineral density measurements were consistent with marked fracture risk. Delayed reduction SDS-PAGE of pepsin-digested collagens from dermal fibroblast cultures demonstrated an anomalous band migrating between alpha 1(I) and alpha 1(III). This band merged with the normal alpha-chains upon prereduction, indicating an unexpected cysteine residue. Cyanogen bromide peptide mapping suggested that the mutation was in the smaller NH2-terminal peptides. cDNA was reverse transcribed from mRNA and amplified by the polymerase chain reaction. A basepair mismatch between proband and control alpha 1(I) cDNA hybrids was detected by chemical cleavage with hydroxylamine:piperidine. The cysteine substitution was thus localized to alpha 1(I) exon 9 within the cyanogen bromide 4 peptide. Nucleotide sequence analysis localized a G----T point mutation in the first position of helical codon 43, replacing the expected glycine (GGT) residue with a cysteine (TGT). The prevalence of similar NH2-terminal mutations in subjects with this phenotype which clinically overlaps idiopathic osteoporosis remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737847      PMCID: PMC442889          DOI: 10.1172/JCI115622

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

Review 1.  Brittle bones--fragile molecules: disorders of collagen gene structure and expression.

Authors:  P H Byers
Journal:  Trends Genet       Date:  1990-09       Impact factor: 11.639

2.  Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta.

Authors:  L D Spotila; C D Constantinou; L Sereda; A Ganguly; B L Riggs; D J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

3.  Substitution of cysteine for glycine within the carboxyl-terminal telopeptide of the alpha 1 chain of type I collagen produces mild osteogenesis imperfecta.

Authors:  D H Cohn; S Apone; D R Eyre; B J Starman; P Andreassen; H Charbonneau; A C Nicholls; F M Pope; P H Byers
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

4.  Direct cloning and sequence analysis of enzymatically amplified genomic sequences.

Authors:  S J Scharf; G T Horn; H A Erlich
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

5.  A substitution of cysteine for glycine 748 of the alpha 1 chain produces a kink at this site in the procollagen I molecule and an altered N-proteinase cleavage site over 225 nm away.

Authors:  B E Vogel; R Doelz; K E Kadler; Y Hojima; J Engel; D J Prockop
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

6.  A lethal variant of osteogenesis imperfecta has a single base mutation that substitutes cysteine for glycine 904 of the alpha 1(I) chain of type I procollagen. The asymptomatic mother has an unidentified mutation producing an overmodified and unstable type I procollagen.

Authors:  C D Constantinou; K B Nielsen; D J Prockop
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

Review 7.  Mutations in collagen genes: causes of rare and some common diseases in humans.

Authors:  H Kuivaniemi; G Tromp; D J Prockop
Journal:  FASEB J       Date:  1991-04       Impact factor: 5.191

8.  A cysteine for glycine substitution at position 1017 in an alpha 1(I) chain of type I collagen in a patient with mild dominantly inherited osteogenesis imperfecta.

Authors:  M E Labhard; M K Wirtz; F M Pope; A C Nicholls; D W Hollister
Journal:  Mol Biol Med       Date:  1988-12

9.  The molecular defect in an autosomal dominant form of osteogenesis imperfecta. Synthesis of type I procollagen containing cysteine in the triple-helical domain of pro-alpha 1(I) chains.

Authors:  W N de Vries; W J de Wet
Journal:  J Biol Chem       Date:  1986-07-05       Impact factor: 5.157

10.  Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype.

Authors:  B J Starman; D Eyre; H Charbonneau; M Harrylock; M A Weis; L Weiss; J M Graham; P H Byers
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more
  10 in total

1.  Genetic and environmental factors affecting bone mineral density in large families.

Authors:  S S Yeap; M Beaumont; A Bennett; N A Keating; D A White; D J Hosking
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

Review 2.  The genetic implication of scoliosis in osteogenesis imperfecta: a review.

Authors:  Gang Liu; Jia Chen; Yangzhong Zhou; Yuzhi Zuo; Sen Liu; Weisheng Chen; Zhihong Wu; Nan Wu
Journal:  J Spine Surg       Date:  2017-12

3.  Osteogenesis imperfecta: a case with hand deformities.

Authors:  Bengi Oz; Nese Olmez; Asuman Memis
Journal:  Clin Rheumatol       Date:  2005-04-23       Impact factor: 2.980

4.  Defective splicing of mRNA from one COL1A1 allele of type I collagen in nondeforming (type I) osteogenesis imperfecta.

Authors:  M L Stover; D Primorac; S C Liu; M B McKinstry; D W Rowe
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

5.  Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen.

Authors:  M C Willing; S P Deschenes; D A Scott; P H Byers; R L Slayton; S H Pitts; H Arikat; E J Roberts
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

6.  Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta.

Authors:  D A Redford-Badwal; M L Stover; M Valli; M B McKinstry; D W Rowe
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

7.  Dentinogenesis Imperfecta and Caries in Osteogenesis Imperfecta among Vietnamese Children.

Authors:  Huong Thi Thu Nguyen; Dung Chi Vu; Duc Minh Nguyen; Quang Dinh Dang; Van Khanh Tran; Hung Le; Son Minh Tong
Journal:  Dent J (Basel)       Date:  2021-04-27

8.  Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model.

Authors:  Ethan Daley; Elizabeth A Streeten; John D Sorkin; Natalia Kuznetsova; Sue A Shapses; Stephanie M Carleton; Alan R Shuldiner; Joan C Marini; Charlotte L Phillips; Steven A Goldstein; Sergey Leikin; Daniel J McBride
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

9.  Subarachnoid hemorrhage secondary to a ruptured middle cerebral aneurysm in a patient with osteogenesis imperfecta: a case report.

Authors:  Toshio Hirohata; Satoru Miyawaki; Akiko Mizutani; Takayuki Iwakami; So Yamada; Hajime Nishido; Yasutaka Suzuki; Shinya Miyamoto; Katsumi Hoya; Mineko Murakami; Akira Matsuno
Journal:  BMC Neurol       Date:  2014-07-23       Impact factor: 2.474

10.  Genetic identification of a common collagen disease in puerto ricans via identity-by-descent mapping in a health system.

Authors:  Gillian Morven Belbin; Jacqueline Odgis; Elena P Sorokin; Muh-Ching Yee; Sumita Kohli; Benjamin S Glicksberg; Christopher R Gignoux; Genevieve L Wojcik; Tielman Van Vleck; Janina M Jeff; Michael Linderman; Claudia Schurmann; Douglas Ruderfer; Xiaoqiang Cai; Amanda Merkelson; Anne E Justice; Kristin L Young; Misa Graff; Kari E North; Ulrike Peters; Regina James; Lucia Hindorff; Ruth Kornreich; Lisa Edelmann; Omri Gottesman; Eli Ea Stahl; Judy H Cho; Ruth Jf Loos; Erwin P Bottinger; Girish N Nadkarni; Noura S Abul-Husn; Eimear E Kenny
Journal:  Elife       Date:  2017-09-12       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.